5 science jobs found in Cambridge, MA

Job Title : Commercial Strategy and Operations Director - Rhinology/Gastro/Allergy Location: Cambridge, MA About the Job Join the team transforming care for people with immune challenges, rare diseases, cancers, and neurological conditions. In Specialty Care, you’ll help deliver breakthrough treatments that bring hope to patients with some of the highest unmet needs.  We are seeking a highly strategic and execution-focused Chief of Staff to partner with the General Manager, US Dupixent RGA (Rhinology/Gastro/Allergy). The Director of Commercial Strategy & Operations role sits at the center of the franchise, driving strategic execution and operational excellence, accelerating business performance, and embedding AI-enabled ways of working across teams. You will act as a force multiplier for the GM ensuring priorities are aligned, decisions are data-driven, and initiatives are executed with speed and rigor. This is a unique opportunity to operate at the highest...

We are seeking an enthusiastic Associate Director, Program & Portfolio Management to drive programs forward at Regeneron Cell Medicines (RCM) through collaborative leadership, providing clarity, direction and a shared sense of purpose to achieve amazing results for patients.  You will join our Program Strategy & Operations (PS&O) team, which oversees the portfolio of work and provides program management at RCM.  In this role, you’ll be a leader on cross-functional program teams (spanning research, clinical, CMC, quality, regulatory, finance, and alliance management) solving complex science and business challenges.  We hope you are excited to focus on programs that are in IND-enabling studies through clinical study execution. As an Associate Director, Program & Portfolio Management at RCM, a typical day might include: Collaborating with Strategic Program Teams to form and manage high-performing cross-functional teams, develop strategic and operational...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...